<div id="readability-page-1"><div> <div> , /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the &#34;Class Period&#34;), of the important June 8, 2026 lead plaintiff deadline. So what: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Medpace's backlog cancellation rate. In fact, defendants continuously touted &#34;well behaved&#34; cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9REM1ODMyNCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMwMjI3UFJfTkVXU19VU1BSX19fX19EQzU4MzI0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9REM1ODMyNCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMwMjI3UFJfTkVXU19VU1BSX19fX19EQzU4MzI0"/></div> </div></div>

MEDP

Rosen Law Firm is reminding investors who purchased Medpace Holdings, Inc. (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, of the June 8, 2026, deadline to lead a securities fraud lawsuit. The firm claims that Medpace misled investors about its backlog cancellation rates, leading to damages when the truth emerged. Investors can join the class action without upfront costs. For more information, contact Phillip Kim, Esq. at 866-767-3653 or via email.

prnewswire

Medpace

VanEck Biotech ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bear 3X

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares US Healthcare Providers

Direxion S&P Biotech Bull 3X

iShares US Medical Devices

iShares Genomics Immunology and Healthcare ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

SPDR S&P Health Equip

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

02:27 ETMEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit